Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation
Annals of Hematology · 2025
DOI: 10.1007/s00277-024-06134-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Hadeer Mohamed Ahmed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Protein-Tyrosine Kinases, Cell Cycle Proteins, Immunotherapy, Adoptive. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ain Shams University.
Abstract (Originalsprache)
Refractory Diffuse Large B-cell Lymphoma (DLBCL) presents a major therapeutic challenge due to its resistance to standard treatments. Engineered T-cells, especially Chimeric Antigen Receptor (CAR) T-cells, have shown promise in overcoming drug resistance. This study investigates the effectiveness of WEE1-engineered T-cells in targeting and eliminating refractory DLBCL in vitro. CAR T-cells were created by transducing a 5th-generation CAR construct designed to recognize WEE1, a surface antigen commonly found on refractory DLBCL cells. The cytotoxic effect of engineered T-cells was tested against Rituximab-resistant DLBCL cells (RR-NU-DUL-1). Apoptosis and cell cycle were evaluated using flow cytometry. Quantitative Real-time PCR (RT-PCR) was used to measure the expression of WEE1, BCL2, and CDK2. The results showed a significant increase in target cell lysis, apoptosis, and necrosis, a significant reduction in the percentage of cells in the G2M phase of the cell cycle, as well as a decrease in gene expression level, indicating strong anti-tumor activity. These findings suggest that CAR T-cell therapy holds great promise for treating refractory DLBCL, offering a potential path for clinical application. This in vitro evaluation highlights the potential of WEE1-engineered T-cells as a targeted treatment strategy for refractory DLBCL, emphasizing their clinical applicability and ability to overcome resistance mechanisms in this aggressive lymphoma subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt.
- Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo, 11566, Egypt.
- Department of Clinical Pathology-Hematology and AinShams Medical Research Institute (MASRI), Faculty of Medicine, Ain Shams University, Cairo, 11566, Egypt. nashwaelkhazragy@med.asu.edu.eg.
Förderung
- Ain Shams University
Zitieren
APA
Ahmed, H. M., Moselhy, S. S., Mohamad, M. I., Soliman, A. F., Hassan, M. N. M., & El-Khazragy, N. (2025). Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation. Annals of Hematology. https://doi.org/10.1007/s00277-024-06134-8
Vancouver
Ahmed HM, Moselhy SS, Mohamad MI, Soliman AF, Hassan MNM, El-Khazragy N. Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation. Annals of Hematology. 2025. doi:10.1007/s00277-024-06134-8
BibTeX
@article{Ahmed2025,
author = {Ahmed, Hadeer Mohamed and Moselhy, Said Salama and Mohamad, Magda I and Soliman, Ahmed F and Hassan, Marwa N M and El-Khazragy, Nashwa},
title = {Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-024-06134-8}
}
EUVIMED